Though sales for Pfizer's (NYSE:PFE) drug Lipitor -- the highest selling drug of all time -- have been down dramatically now that the drug has gone off patent and faces generic competition, this was actually a strong year for Pfizer. It sold its infant nutrition division and is spinning out its animal health division to focus entirely on pharmaceuticals.

In the following video, health care analysts Max Macaluso and Brenton Flynn offer an overview of Pfizer and discuss what investors can expect from the company's drug portfolio and pipeline.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.